RESEARCH ARTICLE
Pleuropulmonary Toxicity of Another Anti-Parkinson’s Drug: Cabergoline
Yolanda Belmonte1, Oriol de Fàbregues2, Marta Marti3, Christian Domingo*, 1, 4
Article Information
Identifiers and Pagination:
Year: 2009Volume: 3
First Page: 90
Last Page: 93
Publisher ID: TORMJ-3-90
DOI: 10.2174/1874306400903010090
Article History:
Received Date: 1/8/2008Revision Received Date: 26/11/2008
Acceptance Date: 11/5/2009
Electronic publication date: 05/6/2009
Collection year: 2009
open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
Abstract
Many drugs may cause toxic injury to the lungs and the pleura. Cabergoline is an ergoline derivative which has been used in Spain for seven years to control symptoms of Parkinson’s disease. We report a patient with dyspnea, bilateral pleural effusion and distal swelling. After a series of complementary tests (blood analysis, chest CT, echocardiogram, pleural tap, pleural biopsy), etiological screening ruled out infection, malignancy or inflammation. Given the patient’s history of three years’ treatment with cabergoline, the drug was considered a possible cause and was progressively withdrawn. The patient’s clinical condition improved and radiological images were disease-free. Using Karch and Lasagna’s classical criteria, we defined a relationship of “probable causality” between the drug and the adverse effects reported.
